Skip Navigation
News & Information Services
 
 
 
 
 
Print This Page
Share this page: More
 

SUPER-EFFECTIVE "JUMPING GENE" CREATED

Johns Hopkins Medicine
Office of Communications and Public Affairs
Media Contact: Joanna Downer
410-614-5105; jdowner1@jhmi.edu
May 19, 2004

SUPER-EFFECTIVE "JUMPING GENE" CREATED
Discovery will reveal secrets of genomic evolution and mammalian genetics

Johns Hopkins scientists have transformed a common "jumping gene" found in the human genome into one that moves hundreds of times more often than normal in mouse and human cells.

Writing in the May 20 issue of Nature, the scientists say their artificial jumping gene sets the stage for creating mice that lack -- at random -- at least one gene, without having to know in advance which gene is being "knocked-out." Such random knock-outs have been critical in studying genetics of other critters and will help shed light on jumping genes' effects -- past and present -- in human health and disease, say the researchers.

"Making this synthetic jumping gene was the home-run experiment we never thought was going to work," says Jef Boeke, Ph.D., professor of molecular biology and genetics and director of the High Throughput Biology Center in Hopkins' Institute for Basic Biomedical Sciences.

Jumping genes, aka retrotransposons, are bits of genetic material that copy themselves and move around in creatures' genomes. They have the potential to disrupt the genes they "land" in and are thought to contribute to the gradual --and perhaps the occasional major -- genetic shifts that drive evolution. While organisms like yeast have just a few dozen jumping genes in their genomes, mammals' genomes contain hundreds of thousands of copies of their jumping genes' DNA, making it difficult to know where or when -- or even if -- a jump has happened.

In a second paper in the same issue of Nature, M.D./Ph.D. candidate Jeffrey Han and Boeke report that the human jumping gene is relatively lethargic because its instructions are hard for cells to read. By replacing some of the gene's instructions with alternatives cells prefer, the researchers made the first highly active, artificial jumping gene that is potentially efficient enough to use in mice.

By inserting the artificial jumping gene into cells of a mouse embryo, scientists should be able to develop mice in which random genes are either silenced completely or simply "quieted" by the jumping gene's intrusion. Studying these mice should reveal the function and identity of the disrupted gene -- in that order.

"The ability to study genetics "backward" -- to disrupt a random gene, determine its role in the animal and then identify it -- has been crucial in understanding genes in fruit flies and yeast, and now we should be able to do it fairly efficiently in mice," says Boeke, whose lab is already starting to develop the necessary technology.

Based on his research, Boeke suggests that the genes' DNA is much more than just "junk" in our genome. Instead, he proposes that, long ago, jumping genes' multiple insertions likely played a major role in establishing the evolutionary shifts that now distinguish mice from men, and that even now their DNA affects how other genes are used.

Both mice and men share jumping genes known as L1 retrotransposons, some of which are "young" and still active, but most of which are "rusting hulks" that account for more than 30 percent of our respective DNA. But even the "young" ones aren't active enough to efficiently introduce genetic changes in mice that can be passed from generation to generation.

The reason, the researchers report, is that the human jumping gene's instructions consist of too much of one DNA building block, and not enough of the three others, an imbalance that bogs down the cell's machinery as it tries to transcribe the DNA into RNA. Instead of plodding through, the machinery just gives up.

To "improve" these genetic instructions, Han took advantage of the fact that multiple sets of three DNA building blocks call for the same protein building block, or amino acid. By swapping most of the gene's original DNA "triplets" with alternatives the cell prefers, Han balanced the gene's building blocks without changing its protein-making instructions. The researchers have filed a provisional patent on the artificial gene.

Han found that mammalian cells readily used the artificial gene, translating its genetic information into RNA and then into the proteins that help the gene jump. In a standard test of jumping genes' activity, the artificial gene jumped upwards of 200 times more often than natural jumping genes.

The discoveries have led the researchers to propose a new way retrotransposons could contribute to evolutionary changes and to disease, besides disrupting a gene entirely. The researchers' bottom line: The prevalence of hard-to-read jumping gene DNA inside a gene may subtly alter the extent to which it is used by the cell.

"Roughly 70 percent of human genes contain some bit of the natural jumping gene's DNA, and big genes have multiple scraps or even complete retrotransposons," says Boeke. "These bits quite likely reduce the amount of RNA made from these genes, and in some cases even change the gene's message and alter the gene's protein-encoding regions."

To test their model's likelihood, postdoctoral fellow Suzanne Szak, Ph.D., surveyed thousands of the most- and least-used human genes. Genes containing more of the jumping gene's hard-to-read DNA were used substantially less than those with shorter and fewer jumping gene bits, she found.

"The presence of jumping gene DNA in genes represents little experiments in the genome -- if the changes benefit or don't harm the cell or the person, they continue to be passed on from cell to cell or generation to generation," adds Boeke. "If not, they would gradually fade from the genome."

The studies were funded by the National Cancer Institute and the Medical Scientist Training Program at Johns Hopkins. Authors on the artificial jumping gene paper are Han and Boeke. Authors reporting the jumping gene's hard-to-read DNA are Han, Szak and Boeke. Szak is now at Biogen Inc.

--JHMI--

On the Web:  http://www.nature.com/nature

 

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424

 

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.